Antibody Sequencing
Receive your quote directly from the manufacturer.
Good, validated antibodies are highly valuable, but hybridomas are easily lost. Storage accidents, genetic drift or contamination can threaten the security of your antibody.
One solution is to sequence your antibody to enable recombinant production. Sequencing an antibody is vital when obtaining intellectual property rights for your sequence, and expands your antibody’s potential with antibody engineering options.
Hybridoma Sequencing
Hybridoma sequencing service is the starting point for protecting your antibody and embarking on antibody engineering projects such as species, isotype and subtype switching or even humanization.
Antibody Protein Sequencing
Sometimes, however, it is too late for hybridoma sequencing as the cell line has been lost or is otherwise unavailable. If sufficient protein is still available, advances in mass spectrometry technology have made it possible to sequence the protein.
Polyclonal Antibody Sequencing
Sequencing polyclonal antibodies in order to secure a precisely defined and reproducible source of antibodies has been an impossibility, until now. Absolute Antibody has partnered with leading industry innovators to offer a polyclonal antibody immortalization service.
Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Antibody expertise and bespoke reagents elevate life sciences research
See how Life Science Group and Absolute Antibody partner to deliver a flexible antibody offering for future-focused life sciences research
